At first, Krista Easom figured the little red bump on her foot was nothing more than a blister.
It didn’t hurt, but after a couple months, it didn’t go away either.
She booked an appointment with a dermatologist to have it removed. She wasn’t worried. Easom, a 24-year-old law school student from New Jersey, was healthy, had no family history of cancer and was getting ready to enjoy some time in her newly adopted city of Chicago.
That’s when she received the results from her dermatologist, who removed a part of the blister and had it tested.
It turns out that little red bump was malignant melanoma, the leading cause of skin cancer death in the United States. It’s a cancer that kills one person every hour, which translates to more than 8,700 Americans each year.
Further tests revealed that Easom’s melanoma had spread to her lymph nodes, which meant she needed a lymphadenectomy to have them removed. This major surgery includes a five-day stay in the hospital followed by an extensive recovery. About half of the patients who undergo this procedure suffer from wound infections because of the 12-inch incision’s hip-to-thigh location.
Easom and her family looked into her options and she was referred to Northwestern Medicine® surgical oncologists Jeffery D. Wayne, MD and Karl Bilimoria, MD, two of the very few surgeons in the country using a minimally invasive procedure to remove groin lymph nodes. This laparoscopic procedure may drastically reduce the recovery rate and chance of infection for patients like Easom.
“Only a handful of surgeons in the country are doing this and it makes a world of difference to the patient,” said Bilimoria, a surgical oncologist at Northwestern Memorial Hospital and an assistant professor of surgery at Northwestern University Feinberg School of Medicine. “Instead of a 12-inch scar, this laparoscopic procedure has only three very small incisions that total less than one inch. Because these incisions are so small, the chance of infection is far less. Instead of a five-day stay in the hospital, Krista went home the day after her surgery.”
Lymph nodes are the most frequent site of the spread of metastatic melanoma and surgically removing them is the only potential for a cure, Wayne said.
“Surgery is the only way to make sure we get all of the cancer,” Wayne said. “We want Krista to move on with her life. The minimally-invasive procedure was by far, the quickest and safest way for her to do that.”
Just a few weeks post-surgery, Easom is already on her way. She will have regular check-ups for awhile but her CT scans and blood tests show that the surgery successfully removed all of her cancer. Easom is participating in a national clinical trial to see if this minimally invasive procedure can help other melanoma patients.
The Latest on: Melanoma
- What is metastasized ocular melanoma? A look at Blanco's fight on December 12, 2017 at 7:19 am
There are only about 2,500 cases of ocular melanoma each year, so experts say it's not surprising not a lot is known about the cancer. Like skin cancer, the disease preys on melanoma cells in eye. Chances of it metastasizing, or spreading to other organs ... […]
- Researchers find new role for SHARPIN protein in melanoma growth on December 12, 2017 at 4:36 am
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex (LUBAC), regulating NFκB and ... […]
- Two Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin Cancer on December 12, 2017 at 4:00 am
Two Centers from The US Oncology Network Adopt iCAD's Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin Cancer Prominent cancer centers expand portfolio of patient-centric treatment solutions with Xoft's innovative ... […]
- Reata Pharmaceuticals : Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma on December 12, 2017 at 2:43 am
(GlobeNewswire) - Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or the Company), a clinical-stage biopharmaceutical company, today announced the presentation of interim data from the ongoing Phase 1b portion of the REVEAL study of omaveloxolone in ... […]
- Global Melanoma Drugs Market to Receive Overwhelming Hike in Revenues by 2016 – 2023 on December 11, 2017 at 9:12 pm
The melanoma drugs market has been segmented based on type of drug therapy into chemotherapy, immunotherapy and, targeted therapy. Albany, NY -- (SBWIRE) -- 12/11/2017 -- According to the American Academy of Dermatology, the prevalence of melanoma is ... […]
- Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma on December 11, 2017 at 3:30 am
IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of interim data from the ongoing Phase 1b portion ... […]
- Novel compound restores immune response in patients with melanoma on December 8, 2017 at 2:07 am
LUGANO-GENEVA, Dec. 8, 2017 - A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017. (1) "Checkpoint inhibitors are a standard of care immunotherapy for metastatic ... […]
- Melanoma Drugs Industry: 2017 Global Market Size, Share, Growth, Trends, 10 Key Companies Profile, Competitive Assessment and Demand Forecast To 2023 on December 5, 2017 at 6:06 am
The Global Melanoma Drugs Market is expected to be growing with a CAGR of XX% till 2023. This report offers comprehensive coverage on global market along with, market trends, drivers, and restraints of the market. This report included a detailed ... […]
- Craig Ceol lab identifies protein associated with metastatic melanoma on December 4, 2017 at 11:31 pm
A study by Craig J. Ceol, PhD, assistant professor of molecular medicine, has revealed that a protein called GDF6, active during early embryo development, plays a primary role in metastatic melanoma. Published in the Journal of Clinical Investigation by Dr ... […]
- Global Melanoma Therapeutics Market Segment-level analysis on December 4, 2017 at 6:43 am
Melanoma denotes to the type of skin cancer which forms from the pigment-consisting cells in the skin. It is more frequent in places with a sunny environment and is the most dangerous of all skin cancers. UV radiations are the main causes of Melanoma. […]
via Google News and Bing News